Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Biocon Launches Yesafili, Aflibercept Biosimilar in the US Market, ETPharma

4 August 2026 · By · Wire by Fusion42

Published

4 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at pharma.economictimes.indiatimes.com →

◆ Verified

Fusion42 · 4 August 2026 · Fusion42 review

Biocon has launched Yesafili, an aflibercept biosimilar, in the US following a settlement and licensing agreement with Regeneron, the original patent holder who had sued Biocon for patent infringement.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face fresh competition in US ophthalmology drugs as Biocon’s entry shows patent settlements can open doors for biosimilar launches in tough markets. This move pressures pricing and access across similar biologics.

◆ Coverage

1 source · 4 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbiosimilarus-marketpatent-settlementbioconaflibercept